Cardiovascular

FDA approves Corifact for congenital Factor XIII deficiency

The U.S. Food and Drug Administration has approved Corifact, the first product for preventing bleeding in people with congenital Factor XIII deficiency. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm243856.htm.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares